Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop

Executive Summary

The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed

You may also be interested in...



Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds

The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting

Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds

The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting

Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies

Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel